The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and the European Society for Medical Oncology Clinical Practice Guidelines for NSCLC recommends a second- or third-generation ALK tyrosine kinase inhibitor (TKI) as the preferred first-line treatment option for these patients [4,5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.